NCT06173466View on ClinicalTrials.gov

Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone

PHASE4CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

February 28, 2024

Study Completion Date

May 30, 2024

Conditions
Liver Cancer
Interventions
DRUG

Liposomal bupivacaine

Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB

DRUG

Bupivacaine Hydrochloride combined with dexamethasone

Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT06173466 - Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone | Biotech Hunter | Biotech Hunter